
Biodesix (BDSX) Stock Forecast & Price Target
Biodesix (BDSX) Analyst Ratings
Bulls say
Biodesix is a company with a competitive position and potential for growth and profitability. Despite its current negative cash flow, the company is focused on hiring, increasing sales, and conserving capital while potentially raising additional capital in the next 12 months. With a potential first-mover advantage and a potential market value of $27 billion annually, the company is working towards achieving profitability and mitigating challenges such as potential competition and changes in reimbursement rates. Additionally, Biodesix is actively pursuing new products and partnerships to drive its growth, but its financial stability may be impacted by decisions from Medicare and commercial payers.
Bears say
Biodesix is a diagnostic solutions company with a single operating segment focused on providing diagnostic testing services and companion diagnostics to biopharmaceutical companies. However, despite strong growth in diagnostic testing revenue, the company's financials remain negative, and there are significant risks to achieving the projected price target of $27, including lower-than-expected revenue growth, competition from potential future market entrants, and the need to maintain favorable reimbursement. Additionally, the company's pipeline tests are dependent on successful clinical evidence generation, and any unfavorable data outcomes could negatively impact future growth prospects.
This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.
Biodesix (BDSX) Analyst Forecast & Price Prediction
Start investing in Biodesix (BDSX)
Order type
Buy in
Order amount
Est. shares
0 shares